Novel Biosensor Uses DNA ‘Barcodes’ to Uncover Disease Signals in Cells
Inspired by bacterial biology, the Gladstone-developed “Detectron” opens up new possibilities for disease research and potentially treatments.

Chair
William H. Younger, Jr.Retired Managing DirectorSutter Hill Ventures
Vice Chair
Stasia A. ObremskeyManaging DirectorRhia VenturesChris Boskin
Media ConsultantKen Coit
Owner, Coit Financial GroupFred Craves, PhD
Founder and Managing Director, Bay City CapitalMarianne De Backer, PhD, MBA
CEO and Director, Vir Biotechnology, Inc.William Evers
Managing Director, AlTi GlobalSakurako D. Fisher
Former President, San Francisco SymphonyLinda Grais, MD, JD
Former President and CEO, Ocera TherapeuticsErin Hoffmann
President and Co-Founder, Additional VenturesLi Lu
Founder and Chairman, Himalaya CapitalDiksha Makan
Senior Vice President of Technology Strategy, ICONIQ CapitalGary Morgenthaler
Partner, Morgenthaler VenturesDeep V. Nishar
Managing Director, General CatalystDenise O’Leary
Former General Partner, Menlo VenturesSteve Richardson
Consultant, Executive Management, Alexandria Real Estate Equities, Inc.Douglas G. Scrivner
Retired General Counsel, AccentureDeepak Srivastava, MD
President, Gladstone Institutes Director, Roddenberry Stem Cell CenterJames B. Tananbaum, MD
Founder, CEO, and Managing Director, Foresite Capital ManagementR. Sanders Williams, MD
President Emeritus, Gladstone InstitutesSharon Winslow
AttorneyMichelle Sibly
TreasurerRobert Wicks
CEO
Ayush Midha, a graduate student in the Jain Lab, studies how the body's metabolism adapts to low oxygen—work that's uncovered backup energy pathways, potential fertility treatments, and a link between oxygen levels and tumor growth.
A new discovery reveals how a SARS-CoV-2 protein reprograms immune cells to accelerate viral spread—and points to a new strategy for therapeutic intervention.
The fellowship provides three years of funding for graduate students pursuing groundbreaking immunology research.
Takahashi is recognized for his pioneering work translating iPS cell technology into a clinically approved therapy for Parkinson’s disease.
Our people are our most important asset. We offer a wide array of career opportunities both in our administrative offices and in our labs.
Open PositionsDiscoveries don’t stay in our labs. Gladstone facilitates spinout companies to advance promising therapies, shortening the path between scientific discovery and helping real patients.
Learn MoreYour gift to Gladstone will allow our researchers to pursue high-quality science, focus on disease, and train the next generation of scientific thought leaders.
Donate Now